Global Hypoperfusion Index (GHI) Algorithm
Edwards Lifesciences, LLC • Cardiovascular • 07/26/2023
Device Purpose
The Global Hypoperfusion Index (GHI) is a software algorithm designed to predict the likelihood of an impending global hypoperfusion event in adult critical care patients by analyzing real-time data from a Swan-Ganz catheter. Utilizing a machine-learning model, it provides an adjunctive, predictive cardiovascular indicator approximately 10-15 minutes before mixed venous oxygen saturation (SvO2) is expected to drop to critical levels, aiding clinicians in anticipating hemodynamic instability.
Summary
The Global Hypoperfusion Index (GHI) algorithm is a software feature for compatible monitoring platforms, intended for use by qualified clinicians in critical care hospital settings. Its primary function is to offer physiological insight into an adult patient's likelihood of experiencing a future global hypoperfusion event, defined as mixed venous oxygen saturation (SvO2) dropping to 60% or below for at least one minute. Designed for both surgical and non-surgical adult patients undergoing advanced hemodynamic monitoring with a Swan-Ganz catheter, the GHI algorithm aims to identify patients at risk for clinical deterioration, as well as those at low risk. The predictions provided are adjunctive, serving as a reference and not as the sole basis for therapeutic decisions. The GHI algorithm employs a machine-learning model that analyzes real-time patient health data to compute the risk of an impending global hypoperfusion event. It is designed to alert clinicians on average 10-15 minutes before the SvO2 is predicted to reach the critical threshold of 60%. The system outputs this risk as an index from 0 to 100, where higher values signify an increased likelihood of the event. The algorithm's performance was validated using clinical data, including prospective analyses of retrospective data from a diverse set of adult surgical patients with invasive monitoring, confirming it met its design and performance specifications.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What specific input parameters from the Swan-Ganz catheter and other real-time patient data are most heavily weighted by the GHI machine-learning model in predicting hypoperfusion?; How does the GHI algorithm's performance (sensitivity, specificity, positive predictive value, negative predictive value) vary across different subpopulations of adult patients (e.g., cardiac surgery vs. sepsis vs. trauma)?; Given the 10-15 minute predictive window, what are the recommended clinical actions or protocols when the GHI indicates an increased likelihood of a hypoperfusion event, and how effective are these interventions in preventing the event or mitigating its severity?; The definition of a global hypoperfusion event is SvO2 ≤ 60% for at least 1 minute. What is the rationale for this specific threshold and duration, and how does the algorithm's predictive accuracy change if these parameters are modified?; How does the GHI algorithm account for or adapt to common interventions in the critical care setting (e.g., vasopressor administration, fluid boluses) that might acutely alter hemodynamic parameters and potentially influence the SvO2 reading?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly